Hodgkin lymphoma and anaplastic large cell lymphoma (ALCL) are two rare but “curable” blood cancers; Hodgkin lymphoma has an 86 percent survival rate and ALCL has an 80 percent survival rate. But what about the other side of the equation – the small population of patients that don’t respond to the standard therapy for these diseases, you might ask? It’s been a tough nut to crack, until now.
For the first time in more than 30 years, there’s hope for this small subgroup of patients. The FDA recently fast-tracked and approved Adcetris, an antibody drug that targets a specific site on lymphoma cells. Adcetris is designed for post-stem cell transplant patients and patients whose cancer resists 1-2 rounds of chemotherapy.
It’s a new day for Hodgkin lymphoma and ALCL patients.
For more information about Hodgkin lymphoma and ALCL, visit www.lls.org.